comparemela.com

Latest Breaking News On - Ascentage pharma group - Page 1 : comparemela.com

EHA 2024 | Results from Five Studies of Ascentage Pharma s Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress

Olverembatinib Improves EFS in TKI-Resistant Chronic Phase CML

Olverembatinib improved event-free survival over best available therapy in patients with TKI-resistant chronic phase CML in a phase 2 trial. Olverembatinib improved event-free survival over best available therapy in patients with TKI-resistant chronic phase CML in a phase 2 trial.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.